Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.

Abstract:

:Breast cancer is a heterogeneous disease that can be divided in subtypes based on histology, gene expression profiles as well as differences in genomic aberrations. Distinct global DNA methylation profiles have been reported in normal breast epithelial cells as well as in breast tumors. However, the influence of the tumor methylome on the previously described subgroups of breast cancer is not fully understood. Here we report the DNA methylation profiles of 80 breast tumors using a panel of 807 cancer related genes interrogating 1505 CpG sites. We identified three major clusters based on the methylation profiles; one consisting of mainly tumors of myoepithelial origin and two other clusters with tumors of predominantly luminal epithelial origin. The clusters were different with respect to estrogen receptor status, TP53 status, ErbB2 status and grade. The most significantly differentially methylated genes including HDAC1, TFF1, OGG1, BMP3, FZD9 and HOXA11 were confirmed by pyrosequencing. Gene Ontology analysis revealed enrichment for genes involved in developmental processes including homeobox domain genes (HOXA9, HOXA11, PAX6, MYBL2, ISL1 and IPF1) and (ETS1, HDAC1, CREBBP, GAS7, SPI1 and TBX1). Extensive correlation to mRNA expression was observed. Pathway analyses identified a significant association with canonical (curated) pathways such as hepatic fibrosis including genes like EGF, NGFR and TNF, dendritic cell maturation and the NF-κB signaling pathway. Our results show that breast tumor expression subtypes harbor major epigenetic differences and tumors with similar gene expression profiles might belong to epigenetically different subtypes. Some of the transcription factors identified, with key roles in differentiation and development might play a role in inducing and maintaining the different phenotypes.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Rønneberg JA,Fleischer T,Solvang HK,Nordgard SH,Edvardsen H,Potapenko I,Nebdal D,Daviaud C,Gut I,Bukholm I,Naume B,Børresen-Dale AL,Tost J,Kristensen V

doi

10.1016/j.molonc.2010.11.004

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

61-76

issue

1

eissn

1574-7891

issn

1878-0261

pii

S1574-7891(10)00128-6

journal_volume

5

pub_type

杂志文章
  • Challenges in circulating tumor cell detection by the CellSearch system.

    abstract::Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method d...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.12.002

    authors: Andree KC,van Dalum G,Terstappen LW

    更新日期:2016-03-01 00:00:00

  • Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

    abstract:PURPOSE:DNA analysis by NGS has become important to direct the clinical care of cancer patients. However, NGS is not successful in all cases, and the factors responsible for test failures have not been systematically evaluated. MATERIALS AND METHODS:A series of 1528 solid and hematolymphoid tumor specimens was tested ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.05.004

    authors: Al-Kateb H,Nguyen TT,Steger-May K,Pfeifer JD

    更新日期:2015-11-01 00:00:00

  • Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation.

    abstract::Breast cancer tissue overexpresses fucosylated glycans, such as sialyl-Lewis X/A (sLeX/A ), and α-1,3/4-fucosyltransferases (FUTs) in relation to increased disease progression and metastasis. These glycans in tumor circulating cells mediate binding to vascular E-selectin, initiating tumor extravasation. However, their...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12163

    authors: Carrascal MA,Silva M,Ramalho JS,Pen C,Martins M,Pascoal C,Amaral C,Serrano I,Oliveira MJ,Sackstein R,Videira PA

    更新日期:2018-05-01 00:00:00

  • Quality-assured research environments for translational cancer research.

    abstract::In order to secure high-quality cancer care for increasing numbers of cancer patients in the upcoming decades, the complete continuum of cancer research and cancer care needs a thorough overhaul, with more emphasis on prevention and early detection, and a greater focus on the development of innovative treatments that ...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12441

    authors: Berns A

    更新日期:2019-03-01 00:00:00

  • Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.

    abstract::Epigenetic silencing of miRNA is a primary mechanism of aberrant miRNA expression in cancer, and hypermethylation of miRNA promoters has been reported to contribute to prostate cancer initiation and progression. Recent data have shown that the miR-193b promoter is hypermethylated in prostate cancer compared with norma...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12536

    authors: Mazzu YZ,Yoshikawa Y,Nandakumar S,Chakraborty G,Armenia J,Jehane LE,Lee GM,Kantoff PW

    更新日期:2019-09-01 00:00:00

  • Autophagy in tumour suppression and promotion.

    abstract::Autophagy, a well-described cellular mechanism for lysosomal degradation of cytoplasmic content, has emerged as a tumour suppression pathway. Recent evidence indicates that the tumour suppressor function of autophagy is mediated by scavenging of damaged oxidative organelles, thereby preventing accumulation of toxic ox...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2009.05.007

    authors: Brech A,Ahlquist T,Lothe RA,Stenmark H

    更新日期:2009-08-01 00:00:00

  • Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.

    abstract::Central nervous system (CNS) metastasis is one of the serious complications of epidermal growth factor receptor (EGFR)-mutant lung cancer, which arises due to poor penetration of the brain-blood barrier by EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Although osimertinib, a third-generation EGFR-TKI, has efficacy agai...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12394

    authors: Kim DH,Choi YJ,Sung KJ,Yoo SA,Sung YH,Kim JK,Choi CM,Yun M,Lee EY,Jin YS,Cook S,Rho JK,Lee JC

    更新日期:2018-12-01 00:00:00

  • Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.

    abstract::Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical responsiveness of tumors have been associated with mechanisms that alter drug entry...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12648

    authors: Melnikova M,Wauer US,Mendus D,Hilger RA,Oliver TG,Mercer K,Gohlke BO,Erdmann K,Niederacher D,Neubauer H,Buderath P,Wimberger P,Kuhlmann JD,Thomale J

    更新日期:2020-04-01 00:00:00

  • Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

    abstract::Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring p...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2010.09.005

    authors: Moreira JM,Cabezón T,Gromova I,Gromov P,Timmermans-Wielenga V,Machado I,Llombart-Bosch A,Kroman N,Rank F,Celis JE

    更新日期:2010-12-01 00:00:00

  • Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer.

    abstract::Mouse models of human cancers may provide a valuable resource for the discovery of cancer biomarkers. We have developed a practical strategy for profiling specific proteins in mouse plasma using low-volume sandwich-immunoassays. We used this method to profile the levels of 14 different cytokines, acute-phase reactants...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2007.06.001

    authors: Forrester S,Hung KE,Kuick R,Kucherlapati R,Haab BB

    更新日期:2007-09-01 00:00:00

  • Allo-reactive T cells for the treatment of hematological malignancies.

    abstract::Several mechanisms can be responsible for control of hematological tumors by allo-reactive T cells. Following allogeneic stem cell transplantation (alloSCT) donor T cells recognizing genetic disparities presented on recipient cells and not on donor cells are main effectors of tumor control, but also of the detrimental...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.10.014

    authors: Falkenburg JH,Jedema I

    更新日期:2015-12-01 00:00:00

  • Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer.

    abstract::Infiltration of the tumor microenvironment by nerve fibers is an understudied aspect of breast carcinogenesis. In this study, the presence of nerve fibers was investigated in a cohort of 369 primary breast cancers (ductal carcinomas in situ, invasive ductal and lobular carcinomas) by immunohistochemistry for the neuro...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.05.001

    authors: Pundavela J,Roselli S,Faulkner S,Attia J,Scott RJ,Thorne RF,Forbes JF,Bradshaw RA,Walker MM,Jobling P,Hondermarck H

    更新日期:2015-10-01 00:00:00

  • The epigenetics of breast cancer.

    abstract::Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype such as the gene expression profile of a cell that are heritable during somatic cell divisions (and sometimes germ line transmissions) but do not involve changes of the DNA sequence itself. Epigenetic phenomena are mediated by se...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2010.04.002

    authors: Jovanovic J,Rønneberg JA,Tost J,Kristensen V

    更新日期:2010-06-01 00:00:00

  • Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.

    abstract::Glycosylation is the stepwise procedure of covalent attachment of oligosaccharide chains to proteins or lipids, and alterations in this process have been associated with malignant transformation. Simultaneous analysis of the expression of all glycan-related genes clearly gives the advantage of enabling a comprehensive...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2009.12.001

    authors: Potapenko IO,Haakensen VD,Lüders T,Helland A,Bukholm I,Sørlie T,Kristensen VN,Lingjaerde OC,Børresen-Dale AL

    更新日期:2010-04-01 00:00:00

  • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

    abstract::Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more real-time representation of a tumor and its molecular heterogeneity than tissue. Howe...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12791

    authors: Charo LM,Eskander RN,Okamura R,Patel SP,Nikanjam M,Lanman RB,Piccioni DE,Kato S,McHale MT,Kurzrock R

    更新日期:2021-01-01 00:00:00

  • Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

    abstract::Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast ca...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.07.005

    authors: Gasch C,Oldopp T,Mauermann O,Gorges TM,Andreas A,Coith C,Müller V,Fehm T,Janni W,Pantel K,Riethdorf S

    更新日期:2016-10-01 00:00:00

  • APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

    abstract::Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12138

    authors: Shah F,Goossens E,Atallah NM,Grimard M,Kelley MR,Fishel ML

    更新日期:2017-12-01 00:00:00

  • DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.

    abstract::The diversity of breast cancers reflects variations in underlying biology and affects the clinical implications for patients. Gene expression studies have identified five major subtypes- Luminal A, Luminal B, basal-like, ErbB2+ and Normal-Like. We set out to determine the role of DNA methylation in subtypes by perform...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2010.11.002

    authors: Kamalakaran S,Varadan V,Giercksky Russnes HE,Levy D,Kendall J,Janevski A,Riggs M,Banerjee N,Synnestvedt M,Schlichting E,Kåresen R,Shama Prasada K,Rotti H,Rao R,Rao L,Eric Tang MH,Satyamoorthy K,Lucito R,Wigler M,Dim

    更新日期:2011-02-01 00:00:00

  • p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

    abstract::Tumour suppressor p53, a master transcriptional regulator determines cell fate through preferential activation/repression of a myriad of genes during stress. Till date, activation and preferential binding of p53 on different promoters was reported to be influenced by the nature, strength and duration of stress which m...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.06.006

    authors: Thakur B,Ray P

    更新日期:2016-10-01 00:00:00

  • TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.

    abstract::Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+ ) T-cell lymphoma is an aggressive neoplasm that is more commonly seen in children and young adults. The pathogenesis of NPM-ALK+ T-cell lymphoma is not completely understood. Wild-type ALK is a receptor tyrosine kinase that is physiologically expressed in ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12088

    authors: Shi W,George SK,George B,Curry CV,Murzabdillaeva A,Alkan S,Amin HM

    更新日期:2017-09-01 00:00:00

  • Targeting breast cancer stem cells.

    abstract::The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of the tumor. Although, the CSC hypothesis does not directly address the cell of origin of cancer, it is...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2010.06.005

    authors: McDermott SP,Wicha MS

    更新日期:2010-10-01 00:00:00

  • Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

    abstract::C13ORF18 is frequently hypermethylated in cervical cancer but not in normal cervix and might serve as a biomarker for the early detection of cervical cancer in scrapings. As hypermethylation is often observed for silenced tumor suppressor genes (TSGs), hypermethylated biomarker genes might exhibit tumor suppressive ac...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2013.02.017

    authors: Huisman C,Wisman GB,Kazemier HG,van Vugt MA,van der Zee AG,Schuuring E,Rots MG

    更新日期:2013-06-01 00:00:00

  • Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.

    abstract::Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2'-deoxycytidine (AZA), a demethylating agent, in combina...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12070

    authors: Vitale G,Dicitore A,Pepe D,Gentilini D,Grassi ES,Borghi MO,Gelmini G,Cantone MC,Gaudenzi G,Misso G,Di Blasio AM,Hofland LJ,Caraglia M,Persani L

    更新日期:2017-08-01 00:00:00

  • TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.

    abstract::cMet is a well-characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody-drug conjugates (ADCs). However, the clinical benefit from cMet-targeted therapy has been limited. We developed a novel cMet-targeted 'third-generation' ADC, TR1...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12600

    authors: Gymnopoulos M,Betancourt O,Blot V,Fujita R,Galvan D,Lieuw V,Nguyen S,Snedden J,Stewart C,Villicana J,Wojciak J,Wong E,Pardo R,Patel N,D'Hooge F,Vijayakrishnan B,Barry C,Hartley JA,Howard PW,Newman R,Coronella J

    更新日期:2020-01-01 00:00:00

  • Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

    abstract:PURPOSE:Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). We sought to characterize the transcriptomic features of LCIS and ILC, with a focus on the identification of intrinsic molecular subtypes of LCIS and the changes involved in the progression ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.12.005

    authors: Andrade VP,Morrogh M,Qin LX,Olvera N,Giri D,Muhsen S,Sakr RA,Schizas M,Ng CK,Arroyo CD,Brogi E,Viale A,Morrow M,Reis-Filho JS,King TA

    更新日期:2015-04-01 00:00:00

  • Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.

    abstract::Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton-interfering pharmacophores, in testicular germ cell tumors (T...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12582

    authors: Steinemann G,Dittmer A,Schmidt J,Josuttis D,Fähling M,Biersack B,Beindorff N,Jolante Koziolek E,Schobert R,Brenner W,Müller T,Nitzsche B,Höpfner M

    更新日期:2019-12-01 00:00:00

  • ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer.

    abstract::Endoplasmic reticulum (ER) stress is an adaptive response to various stress conditions and plays emerging roles in cancer. Activating transcription factor 6 (ATF6), one of the three major ER stress transducers, has been shown to contribute to chemoresistance by altering cancer cell survival. Cancerous inhibitor of pro...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12365

    authors: Liu CY,Hsu CC,Huang TT,Lee CH,Chen JL,Yang SH,Jiang JK,Chen WS,Lee KD,Teng HW

    更新日期:2018-10-01 00:00:00

  • In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

    abstract::The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechan...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12810

    authors: Ariey-Bonnet J,Carrasco K,Le Grand M,Hoffer L,Betzi S,Feracci M,Tsvetkov P,Devred F,Collette Y,Morelli X,Ballester P,Pasquier E

    更新日期:2020-12-01 00:00:00

  • Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

    abstract::The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.03.004

    authors: Cignetto S,Modica C,Chiriaco C,Fontani L,Milla P,Michieli P,Comoglio PM,Vigna E

    更新日期:2016-06-01 00:00:00

  • Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study.

    abstract::Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single-cell molecular analysis is required. We developed the ChimeraX® -i120 platform to facilitate negative enrichment, immunofluorescent labelin...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12876

    authors: Wang PX,Sun YF,Jin WX,Cheng JW,Peng HX,Xu Y,Zhou KQ,Chen LM,Huang K,Wu SY,Hu B,Zhang ZF,Guo W,Cao Y,Zhou J,Fan J,Yang XR

    更新日期:2020-12-10 00:00:00